Orthopedic Surgery Doctors in Glenwood Springs, CO Accepting Medicare

3 Orthopedic Surgery doctors found. Showing 1 - 3

Dr. Daniel O'connor, MD Orthopaedic Surgery Medicare: Medicare Enrolled Practice Location: 1906 Blake Ave, Glenwood Springs, CO 81601 Phone: 970-384-7140    Fax: 970-384-8133

Mr. Eric Matthew Haskell, PA-C Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1906 Blake Ave, Glenwood Springs, CO 81601 Phone: 970-384-7090

Felipe Ituarte, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1906 Blake Ave, Glenwood Springs, CO 81601 Phone: 970-384-8060    Fax: 970-384-8120

News Archive

Corventis' AVIVO Mobile Patient Management System receives the CE mark

Corventis, Inc., a developer of wireless cardiovascular solutions designed to enable early detection, prevention and treatment of cardiovascular conditions, announced CE marking for the company's AVIVO™ Mobile Patient Management System. Physicians and patients in the European Union and other countries that accept CE Mark now have access to the company's noninvasive, wireless solution to evaluate physiological changes and monitor signs of cardiac irregularities in patients away from the hospital.

NTU scientists find potential route to disabling viruses causing severe respiratory diseases

A team of molecular and structural biologists from Nanyang Technological University, Singapore have found a potential new route to disabling respiratory syncytial virus and human metapneumovirus after elucidating the structure of one of its key components.

As vaping illnesses rise, so do pleas to quit-smoking help lines

These are just a few of the messages that teen vapers texted in September to the new "My Life, My Quit" program, which offers phone, text and chat lines to young people trying to quit smoking in 13 states.

Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients

Ocrelizumab (OCR) is a humanized monoclonal antibody that selectively targets CD20+B cells. In a randomized, double-blind, placebo-controlled Phase III study (ORATORIO), OCR significantly reduced disease activity in patients with primary progressive multiple sclerosis (PPMS).

Paratek receives FDA QIDP designation for omadacycline to treat ABSSSI, CABP

Paratek Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic candidate, omadacycline (formerly known as PTK 0796), as a Qualified Infectious Disease Product (QIDP) for both intravenous (IV) and oral formulations in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

Read more Medical News

› Verified 4 days ago